Bank of Montreal Can Acquires Shares of 10,667 Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Bank of Montreal Can acquired a new stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,667 shares of the company’s stock, valued at approximately $74,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of MNMD. Hollencrest Capital Management grew its stake in shares of Mind Medicine (MindMed) by 10,833.3% during the fourth quarter.



Hollencrest Capital Management now owns 7,216 shares of the company’s stock valued at $50,000 after buying an additional 7,150 shares during the last quarter. King Wealth Management Group bought a new position in Mind Medicine (MindMed) in the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS bought a new position in Mind Medicine (MindMed) in the 4th quarter valued at $72,000.

Avantax Advisory Services Inc. purchased a new stake in Mind Medicine (MindMed) in the fourth quarter worth $78,000. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Mind Medicine (MindMed) by 21.

9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,430 shares of the company’s stock worth $87,000 after purchasing an additional 2,230 shares during the last quarter. Hedge funds and other institutional investors own 27.

91% of the company’s stock. Mind Medicine (MindMed) Stock Down 3.1 %Shares of Mind Medicine (MindMed) stock opened at $6.

23 on Friday. Mind Medicine has a 52-week low of $4.70 and a 52-week high of $10.

44. The firm’s 50 day moving average price is $6.24 and its 200-day moving average price is $6.

92. The company has a quick ratio of 9.00, a current ratio of 9.

00 and a debt-to-equity ratio of 0.09. The company has a market cap of $469.

54 million, a P/E ratio of -2.76 and a beta of 2.54.

Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.

33) by ($0.08). During the same period last year, the business earned ($0.

59) earnings per share. On average, sell-side analysts predict that Mind Medicine will post -1.35 EPS for the current fiscal year.

Analysts Set New Price TargetsSeveral equities research analysts have issued reports on MNMD shares. Robert W. Baird lowered their price objective on shares of Mind Medicine (MindMed) from $27.

00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 7th. Evercore ISI started coverage on Mind Medicine (MindMed) in a report on Tuesday, January 28th.

They issued an “outperform” rating and a $23.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $55.

00 price objective on shares of Mind Medicine (MindMed) in a research note on Friday, March 7th. Ten investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.

com, Mind Medicine (MindMed) has a consensus rating of “Buy” and a consensus price target of $25.11.Get Our Latest Report on MNMDInsider Activity at Mind Medicine (MindMed)In other Mind Medicine (MindMed) news, insider Daniel Karlin sold 6,836 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th.

The shares were sold at an average price of $6.74, for a total transaction of $46,074.64.

Following the transaction, the insider now owns 446,177 shares in the company, valued at approximately $3,007,232.98. This represents a 1.

51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Robert Barrow sold 21,208 shares of the firm’s stock in a transaction on Tuesday, March 25th.

The stock was sold at an average price of $6.74, for a total transaction of $142,941.92.

Following the completion of the transaction, the chief executive officer now directly owns 856,556 shares of the company’s stock, valued at approximately $5,773,187.44. This represents a 2.

42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,391 shares of company stock valued at $204,835 in the last ninety days.

Corporate insiders own 2.26% of the company’s stock. Mind Medicine (MindMed) Profile (Free Report)Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.Recommended StoriesFive stocks we like better than Mind Medicine (MindMed)Asset Allocation Strategies in Volatile MarketsMarkets Think Robinhood Earnings Could Send the Stock UpWhat is a Bond Market Holiday? How to Invest and TradeChurchill Downs Stock: Could Tariff Fears Dampen Derby Gains?Conference Calls and Individual InvestorsAT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround.